Physician profile
Kenneth Belitsis
NPI 1427157155
$6,814.61
in general payments reported to CMS, 2019-2025
42 companies · $1,194 in 2025
The $1,194 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,189 · 2020: $481 · 2021: $643 · 2022: $1,054 · 2023: $883 · 2024: $1,371 · 2025: $1,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,222 · Education: $186 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,222.00 |
| Education | $185.59 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $820.48 | 2019-2025 | |
| Abbvie INC. | $819.94 | 2019-2025 | Linzess, Viberzi, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $764.75 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $739.01 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $607.69 | 2019-2025 | Stelara, Tremfya, Simponi |
| Celgene Corporation | $345.44 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $322.28 | 2019-2024 | Dificid |
| Viiv Healthcare Company | $288.45 | 2020-2024 | Dovato |
| Ironwood Pharmaceuticals, INC | $231.55 | 2020-2025 | Linzess |
| Genzyme Corporation | $206.30 | 2022-2025 | |
| Gilead Sciences, INC. | $155.17 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $137.25 | 2022-2023 | Rebyota, Cimzia |
| Lilly USA, LLC | $118.72 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $110.43 | 2022-2025 | Dupixent |
| Daiichi Sankyo INC. | $108.45 | 2019-2024 | Injectafer |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $86.79 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $82.60 | 2024-2025 | Vowst, Zenpep |
| Amgen INC. | $81.70 | 2025 | Uplizna |
| Nestle Healthcare Nutrition INC. | $74.37 | 2021-2023 | |
| Qol Medical, LLC | $68.57 | 2019-2025 | Sucraid |
| Astrazeneca Pharmaceuticals LP | $68.49 | 2025 | Imfinzi |
| Ipsen Biopharmaceuticals, INC | $55.99 | 2024-2025 | Iqirvo, Bylvay |
| Intercept Pharmaceuticals, INC. | $55.51 | 2020-2023 | Ocaliva |
| Ardelyx, INC. | $53.92 | 2022-2025 | Ibsrela |
| Braintree Laboratories, INC. | $52.95 | 2022-2023 | Sutab |
| Allergan, INC. | $47.72 | 2019-2020 | |
| Organon LLC | $41.96 | 2021-2023 | Renflexis |
| Vivus LLC | $37.70 | 2025 | Pancreaze, Qsymia |
| Intra-Sana Laboratories | $29.05 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.53 | 2023-2024 | Cyltezo |
| Evoke Pharma, INC. | $18.11 | 2025 | |
| Ethicon US, LLC | $17.74 | 2019 | |
| Celltrion USA INC. | $16.21 | 2025 | Vegzelma |
| Alnylam Pharmaceuticals INC. | $14.66 | 2025 | Givlaari |
| Ucb, INC. | $14.39 | 2019 | |
| Shionogi INC | $14.07 | 2019 | |
| Romark Laboratories, Lc | $14.00 | 2020 | |
| Phathom Pharmaceuticals, INC. | $13.55 | 2025 | Voquezna |
| Curium US LLC | $13.42 | 2022 | |
| Concordia Pharmaceuticals INC. | $13.00 | 2019 | |
| Medtronic, INC. | $12.80 | 2022 | |
| Shire North American Group INC | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Belitsis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.